Verition Fund Management
ALNY icon

Verition Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Verition Fund Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,900
Closed -$800K – 2311
2022
Q1 		$800K Hold
4,900
– – 0.01% 1616
2021
Q4 		$831K Buy
+4,900
New +$911K 0.01% 1414

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's ALNY Position: Q2 2026 in Review

Verition Fund Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 898 shares — an estimated $297K sold.

Verition Fund Management first reported a position in ALNY in Q3 2014 and held it in 23 quarters. The position peaked at $7.77M in Q3 2025. 792 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Verition Fund Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Verition Fund Management sold 898 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $297K.
  • Verition Fund Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 23 quarters.
  • Verition Fund Management's Alnylam Pharmaceuticals position peaked at $7.77M in Q3 2025.
  • 792 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.